Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
Study Details
Study Description
Brief Summary
A pragmatic, single blinded, randomized, controlled non-inferiority trial of Cytisine versus Nicotine Replacement Therapy for continuous abstinence is conducted in the government run primary health hospitals in Mongolia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Rationale: In Mongolia, smoking cessation assistance in the governmental health sector consists of behavioral counseling and a 3-week regimen of the NRT patch that costs 175 USD. This cost for low income adults limits effectiveness. A 2014 study documented the superiority and lower cost (<20 USD) of Cytisine versus NRT for continuous abstinence. Trial investigators are testing the comparative effectiveness of Cytisine in the "real life setting" of their national health care system and, if proven effective, will include coverage for Cytisine in the national health plan.
Research Question/Objective: To determine whether a 25 day course of Cytisine tablets is at least as effective as 25 days of NRT in helping smokers remain abstinent for at least one month.
Design: A pragmatic, single blinded, randomized, controlled non-inferiority trial.
Setting: Nine governmental primary care centers in Ulaanbaatar, Mongolia, and outskirts.
Participants: Mongolian adult smokers referred to government-run addiction units.
Intervention and procedures: Participants are randomized to 5 weeks of treatment (n=352) or usual care (n=352) and a 6-month follow-up. The treatment consists of a 25-day course of Cytisine tablets and behavioral counseling. Usual care consists of 25 days of NRT and behavioral counseling.
Measurements: The primary outcome is continuous abstinence (< 5 cigarettes smoked since quit date) at 1 month. Secondary outcomes include 7-day point prevalence abstinence rates and adverse events.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Usual Care Group Subjects are asked to completely stop smoking on their quit day and use a daily Nicotine Replacement Therapy (NRT) patch for 25 days. |
Drug: Nicotine Replacement Therapy (NRT)
Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
|
| Experimental: Treatment Group Subjects will start a 25-day course of Cytisine tablets started during the four days before the quit date and are asked to reduce smoking during this time. |
Drug: Cytisine
Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
|
Outcome Measures
Primary Outcome Measures
- Length of abstinence after 25 day course of Cytisine. [One month after quit date]
Continuous abstinence is defined as <5 cigarettes smoked since quit date. Subjects will complete survey to determine number of cigarettes smoked since quit day.
Secondary Outcome Measures
- Length of abstinence after 25 days of NRT [One month after quit date]
Continuous abstinence is defined as <5 cigarettes smoked since quit date. Subjects will complete survey to determine number of cigarettes smoked since quit day.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Seeking smoking cessation treatment
-
Ages 18 years or older
-
Currently smoking > 5 cigarettes per day
-
Willingness to make quit attempt with pharmacotherapy
-
Able to provide verbal and written informed consent
-
Have telephone access
Exclusion Criteria:
-
Pregnancy or currently breastfeeding
-
Current users of NRT (patch, gum, lozenge)
-
Current users of non_NRT smoking cessation pharmacotherapy
-
Enrolled in another smoking cessation program (non-governmental)
-
Clinical disorder that contraindicates use of NRT or Cytisine (heart attack, stroke, severe angina within the past 2 weeks, uncontrolled hypertension, phaeochromocytoma, severe mental illness)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mongolian National University of Medical Sciences | Ulaanbaatar | Mongolia |
Sponsors and Collaborators
- Loma Linda University
- Pfizer
- Mongolian National University of Medical Sciences
Investigators
- Principal Investigator: Pramil N Singh, DrPH, Loma Linda University Health
- Principal Investigator: Davaalkham Dambadarjaa, MD, Mongolian National University of Medical Sciences
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 5170400